Zevra’s CMO Adrian Quartel to Leave July 3, 2026, Consulting Through Year-End
ZVRA•Zevra Therapeutics’ Chief Medical Officer Adrian Quartel will step down effective July 3, 2026, transitioning to a consulting role through December 31, 2026, while the company searches for his successor. Zevra remains on track with EMA review of the arimoclomol MAA and a Phase 3 trial of celiprolol for VEDS.
1. CMO Transition
Adrian Quartel, M.D., FFPM, will step down as Zevra’s Chief Medical Officer on July 3, 2026. He will serve as a consultant through December 31, 2026, while the company conducts a search for his replacement to ensure continuity in its medical strategy.
2. Quartel’s Contributions
During his tenure, Quartel played a key role in securing FDA approval and commercial launch of MIPLYFFA, advancing celiprolol into Phase 3 for Vascular Ehlers-Danlos Syndrome, and submitting the arimoclomol MAA to the European Medicines Agency.
3. Regulatory and Clinical Milestones
Zevra is awaiting the EMA’s decision on the arimoclomol MAA for Niemann-Pick disease type C and is engaged in a Phase 3 trial of celiprolol. The company also plans further dialogue with the FDA in H2 2026 to potentially accelerate development.
4. Corporate Outlook
Zevra remains focused on expanding access to its therapies through geographic growth and advancing its late-stage pipeline. Its commercial launch experience and upcoming milestones underpin management’s confidence in sustaining long-term value creation.
